| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 106.5MM | +8% |
| Gross Profit | 79.8MM | +8% |
| Cost Of Revenue | 26.7MM | +9% |
| Operating Income | -8.7MM | +7% |
| Operating Expenses | 88.5MM | +8% |
| Net Income | -9.8MM | +8% |
| R&D | 20.8MM | +2% |
| G&A | 67.7MM | +10% |
| Amortization | 1.7MM | -0% |
| Interest Expense | 1.8MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with
MASON, Ohio, April 10, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024.
MASON, Ohio, March 26, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to […]
Karl Dahlquist, Chief Legal Officer of AtriCure Inc (NASDAQ:ATRC), has sold 8,231 shares of the company on March 5, 2024, according to a recent SEC filing.
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fourth quarter witnessed a significant easing in financial conditions, which was most notable in the final two months. Class A shares of the fund outperformed the Russell […]
AtriCure ( NASDAQ:ATRC ) Full Year 2023 Results Key Financial Results Revenue: US$399.2m (up 21% from FY 2022). Net...
AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript February 15, 2024 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. AtriCure, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to AtriCure’s Fourth […]
Q4 2023 AtriCure Inc Earnings Call